Clinical Trial Update: Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for STA-9090 (an Hsp90 inhibitor) in metastatic hormone-resistant prostate cancer after docetaxel therapy; completed with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• STA-9090 (ganetespib)

Snippet

Sponsor: Barbara Ann Karmanos Cancer Institute | Conditions: Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2015-04-14